Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?

Abstract

In heart failure (HF) patients, current European Society of Cardiology (ESC) guidelines recommend the use of three loop diuretics (furosemide, torasemide, bumetanide) in order to not only reduce HF hospitalizations but also improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. In addition, for the first time in hypertensive patients, European Society of Hypertension (ESH) guidelines recommend the use of torasemide. This review aimed to summarize the mode of action of loop diuretics, to present their pharmacokinetic characteristics, and to discuss their place in the management of arterial hypertension and heart failure, with special emphasis however on torasemide.

• Authors: Athanasios Manolis, Manolis Kallistratos, Michael Doumas
• Journal: Current pharmaceutical design (Curr Pharm Des) 2021 Vol. 27 Issue 23 Pg. 2714-2721 ISSN: 1873-4286 [Electronic] United Arab Emirates
• PMID: 33823773 (Publication Type: Journal Article, Review)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Diuretics
• Sodium Potassium Chloride Symporter Inhibitors
• Sulfonamides
• Torsemide

Topics

• Diuretics (therapeutic use)
• Heart Failure (drug therapy)
• Humans
• Hypertension (drug therapy)
• Sodium Potassium Chloride Symporter Inhibitors
• Sulfonamides
• Torsemide